Clinical Trial
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
Investigator
Complete title:
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-CoV-2 MONOCLONAL ANTIBODIES AS PRE-EXPOSURE PROPHYLAXIS TO PREVENT COVID-19 IN IMMUNOCOMPROMISED PARTICIPANTS
Study ID:
NCT05074433
Local study ID:
RG1121987
Summary:
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
The secondary objectives of the study are:
•To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population
•To characterize concentrations of casirivimab and imdevimab in serum over time
•To assess the immunogenicity of casirivimab and imdevimab
Trial keywords:
COVID-19
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other eligibility criteria may apply.
Learn more
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact us
For more information about Fred Hutch and to schedule an appointment.
